102 recruiting, 84 unknown, 56 completed, 40 not yet recruiting. 143 Phase 2, 41 Phase 1, 40 Not applicable, 20 Phase 3, 5 Phase 4.
Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment Transarterial chemoembolization, durvalumab and tremelimumab - HCC, Tace | Phase 2 | Not yet recruiting | Chang Gung Memorial Hospital | 90 | 2027-02-01 | 2026-11-02 |
| Effects of Supervised Aerobic Exercise on Biomarkers in Patients With nSCLC Receiving Immunotherapy Exercise - Non-Small Cell Lung Cancer, Aerobic Exercise | Not applicable | Not yet recruiting | Izmir Bakircay University | 78 | 2027-01-04 | 2026-10-21 |
| Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment Thymalfasin - Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 572 | 2026-11-08 | 2026-10-20 |
| RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer Cemiplimab 350 mg IV - Non Small Cell Lung Cancer, Immunotherapy | Phase 2 | Not yet recruiting | The Netherlands Cancer Institute | 30 | 2026-11-01 | 2026-10-05 |
| A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer Short-course radiotherapy, Capecitabine, Oxaliplatin - Rectal Cancer, Radiotherapy | Phase 2 | Not yet recruiting | Tao Zhang | 144 | 2026-11-01 | 2026-10-06 |
| Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer Disitamab Vedotin and Toripalimab, Toripalimab and Nab-Paclitaxel - Bladder (Urothelial, Transitional Cell) Cancer, Antibody-drug Conjugates | Phase 2 | Not yet recruiting | Tianjin Medical University Second Hospital | 150 | 2026-10-20 | 2026-10-23 |
| PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy - Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming | Phase 2 | Recruiting | Samsung Medical Center | 38 | 2026-10-15 | 2026-10-21 |
| FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02) Second-Line Chemotherapy, Radiation Therapy, Cadonilimab (AK104) - Colon Rectal Cancer Adenocarcinoma, Peritoneal (Metastatic) Cancer | Phase 3 | Recruiting | Fudan University | 198 | 2026-10-01 | 2026-10-13 |
| Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study Observation without surgery, Standard-of-care surgery - Non-Small Cell Lung Cancer, Immunotherapy | Phase 1 | Not yet recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 14 | 2026-10-01 | 2026-08-14 |
| Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer Short-Course Radiotherapy, Consolidation treatment (With ICIs), Consolidation treatment (Without ICIs) - Local Advanced Rectal Cancer, Radiotherapy | Phase 3 | Recruiting | Shandong Cancer Hospital and Institute | 180 | 2026-08-15 | 2026-08-18 |
| MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer Adaptive therapy of de-escalation and escalation based on MRD testing and pathological response - Lung Neoplasms, Neoadjuvant Therapy | Not applicable | Recruiting | Peking University People's Hospital | 100 | 2026-08-12 | 2026-10-26 |
| Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial Ipilimumab Injection, Sintilimab injection, Lenvatinib - Renal Cell Carcinoma (Kidney Cancer), Immunotherapy | Phase 2 | Not yet recruiting | West China Hospital | 66 | 2026-08-01 | 2026-07-20 |
| Developing and Testing the Effectiveness of Smart Healthcare Assisted Individualized Symptom Management Education and Home-based Exercise on Frailty, Treatment-related Adverse Events and Quality of Life in Advanced Gastric Cancer Patients Receiving Immunotherapy AI-ISME&HE - Gastric Cancer (GC), Immunotherapy | Not applicable | Not yet recruiting | Taipei Veterans General Hospital, Taiwan | 110 | 2026-07-21 | 2026-07-29 |
| Investigating Real-Time Immunotherapy Symptoms Study Digital remote monitoring intervention, Usual Care - Cancer, Melanoma (Skin Cancer) | Not applicable | Recruiting | University of Pittsburgh | 40 | 2026-06-17 | 2026-08-04 |
| QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer QL1706 + Cisplatin/Paclitaxel Neoadjuvant Therapy - Cervical Cancer, Neoadjuvant Therapy | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 50 | 2026-06-15 | 2026-06-01 |
| Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event TempTraq, VitalTraq - Cytokine Release Syndrome, Neoplasms | Not applicable | Enrolling by invitation | National Cancer Institute (NCI) | 136 | 2026-05-27 | 2026-06-25 |
| A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer Short-course radiotherapy, Long-course radiotherapy, Capecitabine - Rectal Cancer, Total Neoadjuvant Therapy | Phase 3 | Recruiting | Tao Zhang | 444 | 2026-05-15 | 2026-05-13 |
| Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy Non-Small Cell Carcinoma of Lung, Immunotherapy | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 600 | 2026-05-01 | 2026-06-25 | |
| Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study Iparomlimab/Tuvonralimab, Capecitabine, Oxaliplatin - Colon Cancer (Stage II &Amp; III), Immunotherapy | Phase 2 | Not yet recruiting | Sun Yat-sen University | 45 | 2026-04-20 | 2026-04-24 |
| Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study Usui Reiki Intervention - Cancer, Immunotherapy | Not applicable | Recruiting | University of California, Irvine | 12 | 2026-04-20 | 2026-07-10 |
Showing 20 of 309. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (32) · Neoplasms (32) · Carcinoma, Hepatocellular (21) · Esophageal Neoplasms (16) · Colorectal Neoplasms (15) · Lung Neoplasms (13) · Melanoma (12) · Stomach Neoplasms (12) · Rectal Neoplasms (10) · Squamous Cell Carcinoma of Head and Neck (9) · Breast Neoplasms (8) · Carcinoma, Renal Cell (8) · Colonic Neoplasms (8) · Uterine Cervical Neoplasms (8) · Urinary Bladder Neoplasms (7)
Neoplasms by Site (185) · Neoplasms (183) · Digestive System Diseases (90) · Digestive System Neoplasms (88) · Neoplasms by Histologic Type (70) · Gastrointestinal Diseases (65) · Gastrointestinal Neoplasms (63) · Neoplasms, Glandular and Epithelial (54) · Respiratory Tract Diseases (54) · Carcinoma (53) · Lung Diseases (51) · Respiratory Tract Neoplasms (47) · Thoracic Neoplasms (47) · Head and Neck Neoplasms (37) · Bronchial Neoplasms (36)
Immunotherapy (21) · camrelizumab (18) · sintilimab (16) · Drug Therapy (15) · Radiotherapy (15) · tislelizumab (15) · Cisplatin (14) · Bevacizumab (13) · Immune Checkpoint Inhibitors (12) · pembrolizumab (11) · Oxaliplatin (10) · Nivolumab (9) · toripalimab (9) · atezolizumab (8) · Capecitabine (6)
Sun Yat-sen University (18) · Fudan University (12) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (9) · West China Hospital (9) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (6) · Fujian Cancer Hospital (5) · Peking University First Hospital (5) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (5) · Chang Gung Memorial Hospital (4) · Guangdong Provincial People's Hospital (4) · Nanfang Hospital, Southern Medical University (4) · Shandong Cancer Hospital and Institute (4) · Shanghai Chest Hospital (4) · The First Affiliated Hospital with Nanjing Medical University (4) · Ardigen (3)
China (190) · United States (21) · France (15) · Belgium (7) · Netherlands (6) · Poland (6) · Taiwan (6) · Australia (4) · Canada (4) · South Korea (4) · Germany (3) · Italy (3) · United Kingdom (3) · Denmark (2) · Greece (2)
Guibin Qiao, MD (3) · Lei Li, M.D. (3) · Xianshu Gao, MD,PhD (3) · Antoine Desilets, MD, MSc (2) · Els Wauters, MD, PhD (2) · Hailong Li, M.D/Ph.D (2) · Hao Zeng, Doctor (2) · Jinbo Yue, Doctor (2) · Junnian Zheng, M.D/Ph.D (2) · Nehman Makdissy, Professor (2) · Punchama Pacharn, MD (2) · Qing Zhang, Ph.D (2) · Shadmehr Demehri, MD/PHD (2) · Tao Zhang, MD (2) · Xingchen Peng (2)
PMID 23256743, PMID 28541315, PMID 29048935, PMID 15126782, PMID 15875784, PMID 17340590, PMID 20889925, PMID 21075954, PMID 22575238, PMID 23423337, PMID 23452187, PMID 23515080, PMID 23786282, PMID 24357284, PMID 24790793, PMID 24948466, PMID 25279468, PMID 25317870, PMID 25358763, PMID 25539810, PMID 25800393, PMID 25838375, PMID 25846669, PMID 25939063, PMID 26073754, PMID 27099096, PMID 27324428, PMID 27324746, PMID 27389519, PMID 28029303, PMID 28031562, PMID 28123387, PMID 28159490, PMID 28405515, PMID 28434660, PMID 28583311, PMID 28734760, PMID 28796558, PMID 28843072, PMID 29368638, PMID 29398921, PMID 29614760, PMID 29658848, PMID 30293387, PMID 30462163, PMID 30715153, PMID 31085757, PMID 31110702, PMID 31281894, PMID 31679945
2025 (3)